Efficacy and outcomes of clarithromycin treatment for pulmonary MAC disease

Int J Tuberc Lung Dis. 2005 Nov;9(11):1281-7.

Abstract

Setting: Retrospective review of patients with pulmonary Mycobacterium avium complex (MAC) disease treated with clarithromycin.

Objectives: To investigate whether the short-term response to treatment predicts long-term outcomes, and to analyse what explanatory variables are associated with the efficacy and outcome of treatment.

Design: Sputum conversion rates in short- and long-term outcomes were evaluated for 111 patients. Respectively 9 and 10 explanatory variables were analysed for their association with both response and outcomes.

Results: Eighty-four patients (75.7%) showed good short-term response and 94 (82.0%) showed good long-term outcomes. Women and patients with satisfactory nutrition status showed good short-term response. Patients with small lesions and those treated for >12 months after sputum conversion showed good long-term outcomes. Patients who showed good short-term response, in the group with large lesions, showed significantly good long-term outcomes (P = 0.0382).

Conclusion: There were differences between prognostic factors reflecting short-term response and long-term outcomes. The short-term response predicts long-term outcomes in certain groups divided by prognostic factor. To establish standard treatment for pulmonary MAC disease, it is important to determine a standardised method of evaluation of treatment taking such factors into consideration.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Clarithromycin / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mycobacterium avium-intracellulare Infection / drug therapy*
  • Retrospective Studies
  • Time Factors
  • Treatment Outcome
  • Tuberculosis, Pulmonary / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Clarithromycin